Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

Benzer Materyaller

• Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
  Yazar:: Ahn, Myung-Ju, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
  Yazar:: Kim, Youjin, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
  Yazar:: Park, Keunchil, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
  Yazar:: Jung, Hyun Ae, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
  Yazar:: Hyun Ae Jung, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-10-01)